The Food and Drug Administration (FDA) just announced that it has launched the Animal and Veterinary Innovation Agenda (AVIA) as a way to modernize the way the FDA evaluates and supports the development of innovative animal and veterinary products.
The guidelines break for a list of 4 objectives and details that will support actions by the Center for Veterinary Medicine (CVM) to strengthen product development and put into place smart, risk-based approaches as a way to regulate modern animal and veterinary products.
The FDA is planning to go through its animal and veterinary product review programs and projects to reassess and adjust them as needed to account for the diversity of developed products using innovative technologies. According to the organizational release, the agenda will apply to products such as novel food ingredients, animal biotechnology products and tissue-based products (ACTPs), intentional genomic alternations (IGAs) in animals, cell-culture animal food ingredients, and more.
“Novel technologies brought to the forefront in recent years have the potential to set a new course for the way veterinarians and food producers support human and animal health,” said Robert M. Califf, MD, FDA Commissioner, in the release. “The FDA is committed to helping developers bring products that enhance public health, animal health, and food production to market while providing consumers with confidence that they meet the FDA’s high standards.”
“This comprehensive agenda is intended to accelerate smart regulatory pathways and enhance continued public confidence in the FDA’s regulation of these products while avoiding unnecessary barriers to future industry advancements,” he continued.
By modernizing the product review procedures, this will allow the FDA to focus on specific questions that are being raised by upcoming products that are utilizing new and emerging technologies as well as provide clarity and predictability to its review process.
—
Photo Credit: Javier Brosch / Shutterstock.com